SCREENING AND OPTIMIZATION OF VALACYCLOVIR NIOSOMES BY DESIGN OF EXPERIMENTS by S. P., Surya Teja et al.
Original Article 
SCREENING AND OPTIMIZATION OF VALACYCLOVIR NIOSOMES BY DESIGN OF 
EXPERIMENTS 
 
SURYA TEJA S. P.a, MOTHILAL M.a*, DAMODHARAN N.a, JAISON D.b 
aDepartment of Pharmaceutics, SRM College of Pharmacy, SRM University, Chennai, India, bNanotechnology Research Center, SRM 
University, Chennai, India 
Email: mothipharma78@gmail.com   
Received: 14 Sep 2017, Revised and Accepted: 28 Nov 2017 
ABSTRACT 
Objective: The objective of the study was to perform a screening, optimization of valacyclovir niosomal formulation to achieve a sustained release 
of drug using the design of experiments by 32 full factorial design. 
Methods: Valacyclovir loaded niosomes were prepared using thin film hydration method by varying the ratio of Span 60 and Cholesterol. The 
prepared niosomes were evaluated for vesicle size, entrapment efficiency, cumulative drug release, fourier transformed infrared spectroscopy 
(FTIR), zeta potential and surface morphology by field emission scanning electron microscopy (FESEM).  
Results: The valacyclovir was successfully encapsulated and its entrapment efficiency ranged from 36.70 % to 50.62 %. The average vesicle size of 
the niosomes was found to be 431 to 623 nm. At 8th hour the drug release varied from 77.50% to 96.31 %. The optimized niosomes were 
multilamellar with a surface charge potential of about-43.2 mV. The studies revealed that the interaction of cholesterol and surfactant had a 
substantial effect on vesicle size, entrapment efficiency and drug release from the niosomes. The release kinetics of the optimized niosomes 
followed zero order kinetics with fickian diffusion controlled mechanism. The stability studies were performed for the optimized formulation and 
found that the formulation is stable at 4°C ± 2°C. 
Conclusion: Model equations were developed for the responses. No significant difference was observed between the predicted and observed value, 
showing that the developed model is reliable. 
Keywords: Design of Experiments, Full factorial design, Niosomes, Optimization, Valacyclovir 




Globally the genital infection is more frequent, caused by Herpes 
virus HSV 1 and HSV 2 depending on the different geographical 
regions [1]. In general, the infection rate is higher in developing 
countries and its prevalence may reach up to 50 % in near future [2, 
3]. Valacyclovir is an L-valyl ester of acyclovir which is rapidly 
converted in vivo to acyclovir that is used in the management of 
herpes zoster (shingles) and herpes simplex infections [4]. The 
achievement of plasma concentration of acyclovir from the oral 
administration of prodrug valacyclovir is 3-5 fold higher than 
acyclovir due to active transport mechanism in human intestine [5, 
6]. The exact mechanism of increased absorption is not completely 
determined, yet it may be due to the involvement of intestinal 
dipeptide transporters, followed by hasty ester hydrolysis in small 
intestine and liver. Pharmacokinetic properties of valacyclovir are 
well established [6, 7]. Valacyclovir 1000 mg is available in the 
market in the form of caplet and due to its short half-life, the 
repeated dosage is required, which is difficult to swallow for the 
paediatrics and geriatrics [8].  
The prodrug valacyclovir may undergo partial hydrolysis by 
esterases in the stomach which results in a decrease in oral 
bioavailability. The bioavailability of the valacyclovir can be 
increased by controlling the drug release and concentrating the drug 
in the targeted site [9]. Various approaches to target and control the 
drug release includes microspheres, microemulsions, magnetic 
microcapsules, antibody loaded drug delivery, implantable pumps, 
nanoparticles, liposomes and niosomes [10]. 
Niosomes is a class of molecular clusters, a closed lamellar bilayer 
vesicular structure formed by self-assembled non-ionic surfactants in 
the aqueous phase with or without the incorporation of cholesterol as a 
stabilizer and dicetyl phosphate as a negative charge inducer [11, 12]. 
Niosomes have a unique structure and are chemically stable to oxidative 
degradation thus it can be an effective novel drug delivery system with 
an ability to load both hydrophilic and lipophilic drugs [9]. 
The good experimental design is important in formulation 
development studies and other pharmaceutical processes [13]. Full 
factorial design aids to study the entire process factors affecting the 
response and gives information about the relation between the factors 
and interaction between them. This information will be useful in 
reproducibility of study and in the industrial scale-up process [14]. 
The goal of this study was to develop a promising and easily 
administrable formulation of valacyclovir for paediatrics and geriatrics. 
The objective of the current research work was to study the effect of 
surfactant and cholesterol concentration in the formulation of 
valacyclovir loaded niosomes by employing 32 full factorial design. The 
study also focuses on optimization and validation of a reliable model for 
the desired response by using Design Expert, 10.0.03 [Stat-Ease. Inc].  
MATERIALS AND METHODS 
Materials 
Valacyclovir hydrochloride was received as a gift sample from 
Orchid Pharma Ltd., Chennai. Span 60 and Cholesterol were 
obtained from Loba Chemie Pvt. Ltd, Mumbai. Methanol was 
obtained from Honyon International, Inc, China. Chloroform was 
obtained from Rankem, New Delhi. Dialysis Membrane was obtained 
from Himedia Laboratories, Mumbai. All the chemicals and reagents 
used were of the analytical and pharmaceutical grade. 
Drug-polymer compatibility studies by Fourier transform 
infrared spectroscopic analysis 
The drug, drug-excipient mixtures were mixed thoroughly with 
previously dried potassium bromide (IR grade) and compressed in a 
hydraulic press to form transparent pellets. The samples were 
scanned from 4000 to 400 cm-1 at ambient temperature using FTIR 
(Shimadzu, Japan) [15]. 
Design of experiments 
32 A factorial design was adopted based on the preliminary studies for 
the preparation of valacyclovir loaded niosomes. The concentration of 
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span 60 (X1) and cholesterol (X2) were chosen to study their effect 
on percentage entrapment efficiency (Y1), In vitro drug release at 8th 
hour (Y2), vesicle size (Y3). The factors are studied at three levels-1, 
0 and 1 indicating low, medium and high respectively. The statistical 
optimization procedure was accomplished with the help of Design-
Expert version 10 (Stat-Ease, Inc. USA). The software performs 
response surface methodology including multiple regression 
analysis, ANOVA and statistical optimization. The dependent 
variables, their constraints and goals to be achieved are depicted in 
table 1 [16-19]. 
 
Table 1: Independent and dependent variables of 32factorial design 
Independent variables 
Factors Coded levels 
-1 0 +1 
X1: Span 60 (mg) 215 322.5 430 
X2: Cholesterol (mg) 115 156.5 198 
Dependent Variables 
Responses Constraints 
Y1: Entrapment Efficiency (%) Maximum 
Y2: In vitro Drug release at 8th hour (%) Maximum 
Y3: Vesicle Size (nm) Minimum 
 
Preparation of valacyclovir loaded niosomes 
Valacyclovir loaded niosomes were prepared using thin film 
hydration method [19-21]. Span 60 and cholesterol in different 
ratios were dissolved in 10 ml of chloroform and methanol 
mixture (2:1 v/v) in a round bottom flask. 100 mg of valacyclovir 
was separately dissolved in 5 ml of chloroform and methanol 
mixture (2:1 v/v) and added to surfactant mixture. The solvents 
were evaporated under vacuum at 40°C in a rotary evaporator 
(Buchi, Switzerland) at 120 rpm until a smooth and thin film 
formed on the wall of the flask. After ensuring complete removal of 
volatile solvents, hydration of the surfactant film was carried out 
using 10 ml of distilled water at 60°C ± 2°C with mechanical 
agitation to form a niosomal suspension. The resulting niosomal 
suspension was sonicated (Equitron, Mumbai) in 3 cycles of 1/1 
min on/off cycles leading to the formation of multilamellar 
niosomes. The obtained niosomal suspension was left to mature 
overnight at 2°C - 8°C and stored under refrigeration for further 
studies. The composition of 9 formula based on 32 factorial design 
are represented in table 2. 
 
Table 2: Experimental design of 32factorial design 
Formulation code Factors 
X1 X2 
VN1 -1 -1 
VN2 -1 0 
VN3 -1 +1 
VN4 0 -1 
VN5 0 0 
VN6* 0 0 
VN7 0 +1 
VN8 +1 -1 
VN9 +1 0 
VN10 +1 +1 
X1 and X2–coded levels of span 60 and cholesterol respectively, *Center point formulation 
 
Characterization of valacyclovir loaded niosomes 
Valacyclovir loaded niosomal formulations were characterized with 
respect to vesicle size, entrapment efficiency and In vitro drug 
release. The surface characteristics such as surface morphology and 
surface charge of the optimized formulation were studied. 
Determination of vesicle size 
Niosomal suspension was diluted with pH 7.4 phosphate buffer and 
the mean vesicle size and polydispersity index of the valacyclovir 
loaded niosomes was determined by dynamic light scattering 
technique using malvern zetasizer, (Malvern Inc, UK) at room 
temperature by keeping the angle of detection at 90 ° [16].  
Determination of entrapment efficiency 
Entrapment efficiency of the valacyclovir loaded niosomes was 
determined by centrifugation method using a centrifuge with 10000 
rpm maintained at 4 °C for 10 min. The supernatant is filtered by 
using Whatman filter paper to get a clear fraction. From the filtrate, 
the unentrapped valacyclovir was determined by UV-Visible 
spectrophotometer (Shimadzu, Japan) at 235 nm [21]. Each 
experiment was carried out in triplicate. The entrapment efficiency 
was calculated from the formula given in the equation 1. 
 
In vitro release of valacyclovir loaded niosomes 
USP Dissolution apparatus II (paddle type) was used to perform the 
in vitro drug release. Phosphate buffer pH 7.4 maintained at a 
temperature 37.5°C ± 0.5°C was used as a dissolution medium. The 
formulated valacyclovir loaded niosomal suspension was pipetted 
into prewashed dialysis tubing (Himedia, the cutoff value 12000 
daltons), tied to the paddle of dissolution apparatus and rotated at a 
speed of 50 rpm. The samples are withdrawn at predetermined time 
intervals for 8 h. Samples were analyzed for drug content by using 
UV-Visible spectroscopy at 235 nm [22]. 
Statistical analysis 
Different polynomial equations for different models were generated 
by using the multiple regression analysis in 32 factorial design with 
the interacting term and regression coefficient for evaluating the 
responses. The responses were analysed using quadratic equation 2, 
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………. (2) 
Where Y is response evaluated, b0 is the arithmetic mean of all 9 
responses; bi is the estimated coefficients of independent variables. 
P value gives a significant level of each term considering null 
hypothesis is true. P value less than 0.05 is considered to be 
significant [16, 21]. 
Surface morphology study 
The surface morphology of valacyclovir loaded niosomes was 
analyzed by mounting the suspension in the aluminium stub and 
then examined under field emission scanning electron microscopy 
(Quanta FEG, USA) at 10 kV accelerating voltage [23]. 
Determination of surface charge  
The surface charge of the colloidal valacyclovir loaded niosomes was 
determined by using zeta potential analyzer (Malvern, UK) based on 
dynamic light scattering technique at room temperature [24].  
Determination of release kinetics  
The mathematical models, zero order, first order, Korsmeyer-
peppas, higuchi and hixson-crowell were fitted to the dissolution 
data of optimized valacyclovir loaded niosomes to analyse the 
rate, mechanism and pattern of drug release.  
The equations representing the mathematical models are shown 
in table 3 [25, 26]. 
Stability of valacyclovir loaded niosomes 
Stability of the valacyclovir loaded niosomes was performed on the 
freshly prepared optimized formulation at 4°C ± 2 °C, 25°C ± 2°C and 
40°C ± 2°C for 3 mo to investigate the drug leaching from the 
niosomes.  
At different time points, the entrapment efficiency of the 
valacyclovir loaded niosomes was observed for different storage 
conditions [16, 27]. 
 
Table 3: Mathematical models for release kinetics 
Model Equation 
Zero Order Qt = Q0+k0t 






Where Q0-initial amount of drug in solution, Qt-amount of drug released at time t, K0-zero order release constant (Concentration/time), C0–initial 
amount of drug in formulation, C–amount of drug remaining in the formulation at time t, k-first order rate constant, Cs-cumulative amount of drug 
release at time t, t–time in hours, Ks–Hixson Crowell release constant, QA-amount of drug released at time t per unit area, KH–Higuchi dissolution 
constant, Mt/M∞-fraction of drug released at time t, K–release rate constant, n-release exponent 
 
RESULTS AND DISCUSSION 
Drug-polymer compatibility studies by fourier transform 
infrared spectroscopic analysis 
The FTIR spectra of valacyclovir (fig. 1) shows significant peaks 
at 3430 cm-1 (N-H stretching), 3323 cm-1 (O-H stretching), 2932 
cm-1 (C-H stretching), 1745 cm-1(C=O stretching), 1657 cm-1(N-H 
bending), 1085 cm-1 (C-N stretching) and 1036 cm-1(C-O 
stretching).  
The Valacyclovir-cholesterol, valacyclovir-span 60 mixture 
showed all the peaks of valacyclovir without any tangible 
shifting ensuring the compatibility of the drug with excipients. 
 
 
Fig. 1: Fourier transform infrared spectra of (a) valacyclovir, (b) valacyclovir+cholesterol, (c) valacyclovir+span 60 
 
Vesicle size 
The vesicle size of various valacyclovir loaded niosomal 
formulations was ranged from 431 nm to 623 nm with a 
polydispersity index ranging from 0.56 to 0.82, indicating a 
narrow size distribution of formulated niosomes (fig. 2C). From 
the interaction plot, it is evident that the increase in the 
concentration of cholesterol increases the vesicle size (fig. 3C). At 
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low concentrations of cholesterol and span 60, it is believed to be 
closely packed, as the concentration of cholesterol increases, the 
hydrophobicity of the bilayer membrane increases thereby 
increasing vesicle size [21]. 
 
 
Fig. 2: Observed value of responses A) entrapment efficiency Y1 (%); B) cumulative drug release at 8th hour Y2 (%); C) mean vesicle size Y3 
(nm), the values are given as mean±SEM; where n=3 
 
Entrapment efficiency 
It was found that the Entrapment efficiency of the various valacyclovir 
loaded niosomal formulations were ranged from 36.70 % to 50.62 % 
(fig. 2 A). The entrapment efficiency of niosomal formulations increases 
with increase in cholesterol concentration, a further increase in the 
concentration of cholesterol decreases its entrapment efficiency (fig. 3 
A). This may be due to two possible reasons, firstly with an increase in 
cholesterol, the hydrophobicity of bilayer vesicles increases, thereby 
decreasing vesicle permeability. Secondly higher cholesterol content 
may compete with the drug molecules for packing space within the 
bilayer, thereby excluding the drug as amphiphiles [20, 21]. 
 
 
Fig. 3: Interaction plot showing the effect of X1 and X2 on (A) entrapment efficiency Y1 (%), (B) cumulative drug release Y2 (%), (C) vesicle 
size Y3 (nm), the values are given as mean±SEM, where n=3 
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In vitro drug release 
The cumulative in vitro drug release was performed in phosphate 
buffer pH 7.4 by dialysis method. It was observed that the drug 
release of all the formulations ranged from 77.5 % to 96.31 % at 8th 
hour (fig. 2 B) with an initial burst release at 0.5 hour (fig. 4), this 
may be due to the release of the surface drug. The increase in the 
concentration of span 60 and cholesterol decreases the drug release 
of the formulated niosomes (fig. 3 B). This might be due to the fact 
that increased surfactant acts as a depot, whereas the increase in 
cholesterol hardens the vesicle and thereby reducing the leakage of 
the drug into the medium [28]. 
 
Fig. 4: In vitro drug release of valacyclovir loaded niosomes, the values are given as mean±SEM; where n=3 
 
Optimization of valacyclovir loaded niosomes 
32 factorial design was employed to study, optimize and evaluate 
the mean, interaction and quadratic effects of the selected 
variables on the response for the valacyclovir loaded niosomes. It 
was observed that quadratic model was best fitted for the 
responses Y1, Y2 and Y3. 
Mathematical modeling 
Entrapment efficiency (Y1), cumulative drug release (Y2) and vesicle 
size (Y3) were analysed and mathematical model for each response 




The inference from model analysis suggests that the increase in the 
concentration of cholesterol decreases the entrapment efficiency 
and increases the vesicle size, whereas an increase in span 60 
decreases the cumulative drug release.  
ANOVA analysis 
ANOVA for entrapment efficiency (Y1) and vesicle size (Y3) indicate 
that both surfactant (X1) and cholesterol (X2) were significant terms 
with a P value less than 0.5 (table 4), thus a null hypothesis was 
rejected and alternate hypothesis was proposed: both the variables 
have significant effect on entrapment efficiency and vesicle size. 
 ANOVA for cumulative drug release (Y2) indicates that the 
surfactant (X1) has a significant effect on the release of drug from 
valacyclovir loaded niosomes. 3D surface plots (fig. 5) represent the 
variations in response with respect to the change in the level of 
surfactant (X1) and cholesterol (X2). 
 
 
Fig. 5: Surface response plot showing the effect of X1 and X2 on (A) entrapment efficiency Y1 (%), (B) cumulative drug release Y2 (%), (C) 
vesicle size Y3 (nm) 
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Prediction and validation of the optimized formulation 
An optimized formula (OVN) of valacycovir loaded niosomes with 
desirability factor closely related to one, which fulfil the 
requirement of achieving maximum entrapment efficiency, 
maximum drug release at 8th hour and minimum vesicle size is 
selected. To validate the calculated optimal factor levels and their 
predicted responses, the optimized formulation is prepared and 
evaluated. From the results (table 5), it can be concluded that 
optimized formula showed vesicle size, entrapment efficiency and 
drug release profile as predicted from the model equations 
developed by the present study without significant difference. 
 
Table 4: ANOVA table for responses 
Factor % Entrapment efficiency Y1 % Cumulative drug release Y2 Vesicle size Y3 
P value P value P value 
Model  0.0018*  0.0123* 0.0073* 
X1  0.0229*  0.0015*  0.0383* 
X2  0.0127* 0.1002  0.0009* 
X1 X2 0.8482 0.4755 0.5336 
X12 0.0118 0.1120 0.1803 
X22  0.0004* 0.6601 0.3574 
*significant effect of factors on individual responses (p value<0.05) 
 
Table 5: Validation of optimized formulation by experimental design 
Factor Coded value Actual value (mg) Response Predicted value Experimental value % Error 
Span 60 (X1) -0.21 300 Entrapment Efficiency (Y1) 45.3 % 44.1 % 3.19 % 
Cholesterol(X2) -0.64 133.26 Cumulative drug release (Y2) 92.4 % 89.6 % 1.96 % 
   Vesicle size (Y3) 463 nm 479 nm 2.95 % 
 
Surface morphology 
The FESEM of the optimized niosomal formulation showed that the 
vesicles are spherical with rough surfaces (fig. 6). It is also observed that 
the prepared valacyclovir loaded niosomes are multilamellar in nature. 
 
 
Fig. 6: Field emission scanning electron microscopy of the 
optimised formulation (OVN) 
 
Surface charge 
The potential of the stability of niosomes depends on the magnitude 
of the zeta potential. The zeta potential measurement of the 
optimized niosomal formulation showed-43.2 mV (fig. 7). This value 
is sufficiently high for electrostatic stabilization as the zeta potential 
increases, the charged particles repel one another and become more 
stable against aggregation [29]. 
 
 
Fig. 7: Zeta potential of optimised formulation OVN 
 
Drug release kinetics 
The release kinetics of the optimized formulation (table 6) followed 
zero order kinetics. Higuchi’s correlation coefficient showed that the 
drug release is proportional to the square root of time indicating 
that valacyclovir release is diffusion controlled. The n value from the 
korsemeyer peppas model for valacyclovir niosomal formulation 
was 0.3209 which confirms the fickian diffusion. 
  
Table 6: Release kinetics of the optimized valacyclovir loaded niosomal formulation (OVN) 
Formulation Higuchi Korsemeyer Peppas Zero Order First Order Hixson-Crowell 
r2 n r2 r2 r2 r2 
OVN 0.9197 0.3209 0.9532 0.8135 0.9203 0.9167 
 
Stability studies 
Stability of the valacyclovir loaded niosomes was performed on the 
freshly prepared optimized formulation at 4 °C±2 °C, 25 °C±2 °C and 
40 °C±2 °C for 3 mo (table 7). At the end of 3rd month the 
entrapment efficiency of optimized niosomes at 4 °C±2 °C, 25 °C±2 
°C and 40 °C±2 °C was found to be 48.12 %, 46.34 % and 43.19 % 
respectively. As expected, at refrigerated conditions the amount of 
drug retained in the niosomes was more than the accelerated 
conditions.
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Table 7: Stability of the optimized valacyclovir loaded niosomes 
Formulation Conditions Entrapment efficiency (%) 
1 mo 2 mo 3 mo 
OVN 4 °C±2 °C 49.86±0.7159 48.32±0.7851 48.12±0.8371 
25 °C±2 °C 47.96±0.9006 47.21±1.0738 46.34±1.1085 
40 °C±2 °C 45.81±0.9064 44.34±0.9526 43.19±0.9757 
mean±SEM, where n=3 
 
CONCLUSION 
32 full factorial design was prepared and evaluated to study factors 
influencing the formulation of niosomes. Surfactant: drug ratio 
(X1) and cholesterol level (X2) were taken as independent 
variables. The independent variables selected were % entrapment 
efficiency (Y1), Drug release at 8th hour (Y2) and Particle size (Y3). 
Statistical analysis of results was done using Design Expert, 10.0.3 
[Statease. Inc]. The study revealed that cholesterol level had a 
significant effect on entrapment efficiency and vesicle size, 
whereas surfactant has a significant effect on the cumulative drug 
release. Based on the mathematical modelling an optimized 
formulation was identified and prepared. Results indicated that 
there is no significant difference between the predicted and 
observed value, showing that the model is reliable. Results 
suggested that the proposed 32 factorial model is suitable for the 
preparation of sustained release valacyclovir loaded niosomes 
thereby decreasing the frequency of dosage and increasing patient 
compliance for the treatment of herpex simplex virus and 
Varicella-zoster virus infections.  
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